Lifecore Biomedical (LFCR) Competitors $7.52 -0.25 (-3.22%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.52 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LFCR vs. SPRY, DNTH, ORIC, UPB, SYRE, PHAR, URGN, CRMD, ATAI, and QUREShould you be buying Lifecore Biomedical stock or one of its competitors? The main competitors of Lifecore Biomedical include ARS Pharmaceuticals (SPRY), Dianthus Therapeutics (DNTH), Oric Pharmaceuticals (ORIC), Upstream Bio (UPB), Spyre Therapeutics (SYRE), Pharming Group (PHAR), Urogen Pharma (URGN), CorMedix (CRMD), atai Life Sciences (ATAI), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Lifecore Biomedical vs. Its Competitors ARS Pharmaceuticals Dianthus Therapeutics Oric Pharmaceuticals Upstream Bio Spyre Therapeutics Pharming Group Urogen Pharma CorMedix atai Life Sciences uniQure Lifecore Biomedical (NASDAQ:LFCR) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings. Is LFCR or SPRY more profitable? Lifecore Biomedical has a net margin of -31.70% compared to ARS Pharmaceuticals' net margin of -42.74%. ARS Pharmaceuticals' return on equity of -21.85% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Lifecore Biomedical-31.70% -846.51% -13.03% ARS Pharmaceuticals -42.74%-21.85%-15.88% Which has more volatility and risk, LFCR or SPRY? Lifecore Biomedical has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Does the media refer more to LFCR or SPRY? In the previous week, ARS Pharmaceuticals had 7 more articles in the media than Lifecore Biomedical. MarketBeat recorded 11 mentions for ARS Pharmaceuticals and 4 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.81 beat ARS Pharmaceuticals' score of 0.63 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in LFCR or SPRY? 83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 32.2% of Lifecore Biomedical shares are held by company insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, LFCR or SPRY? ARS Pharmaceuticals has lower revenue, but higher earnings than Lifecore Biomedical. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifecore Biomedical$128.87M2.18-$38.72M-$1.31-5.74ARS Pharmaceuticals$112.34M8.82$8M-$0.49-20.47 Do analysts rate LFCR or SPRY? Lifecore Biomedical currently has a consensus price target of $8.00, indicating a potential upside of 6.38%. ARS Pharmaceuticals has a consensus price target of $32.50, indicating a potential upside of 224.03%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Lifecore Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryARS Pharmaceuticals beats Lifecore Biomedical on 11 of the 17 factors compared between the two stocks. Get Lifecore Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for LFCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFCR vs. The Competition Export to ExcelMetricLifecore BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$281.31M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-5.7421.5775.5726.02Price / Sales2.18254.90461.9291.11Price / CashN/A44.4425.8129.91Price / Book188.009.6112.526.25Net Income-$38.72M-$53.29M$3.29B$270.76M7 Day Performance3.16%0.57%0.78%2.54%1 Month Performance2.04%4.56%4.56%5.73%1 Year Performance45.17%10.44%66.82%25.85% Lifecore Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFCRLifecore Biomedical1.1012 of 5 stars$7.52-3.2%$8.00+6.4%+45.2%$281.31M$128.87M-5.74690SPRYARS Pharmaceuticals2.5953 of 5 stars$10.48-2.1%$32.50+210.2%-24.6%$1.04B$89.15M-21.4790DNTHDianthus Therapeutics3.1027 of 5 stars$32.04+0.8%$59.50+85.7%+28.3%$1.02B$6.24M-9.7380Trending NewsAnalyst ForecastORICOric Pharmaceuticals4.5618 of 5 stars$10.46-0.4%$17.29+65.3%+9.0%$1.02BN/A-5.5380Positive NewsUPBUpstream Bio1.8338 of 5 stars$18.78+0.2%$56.50+200.9%N/A$1.01B$2.37M0.0038Positive NewsSYRESpyre Therapeutics2.2595 of 5 stars$16.46-3.2%$53.40+224.4%-46.7%$1.01B$890K-4.9373Positive NewsPHARPharming Group2.2294 of 5 stars$14.520.0%$30.00+106.7%+95.7%$1.00B$297.20M-112.62280Short Interest ↑URGNUrogen Pharma4.0694 of 5 stars$21.24-0.8%$32.00+50.7%+43.2%$997.13M$90.40M-6.49200Analyst UpgradeCRMDCorMedix3.9122 of 5 stars$13.20+3.5%$18.00+36.4%+86.2%$997.10M$43.47M17.8130Trending NewsAnalyst UpgradeInsider TradeATAIatai Life Sciences2.8782 of 5 stars$4.57+1.2%$11.25+146.0%+256.2%$982.74M$2.31M-6.6480Positive NewsQUREuniQure3.2074 of 5 stars$17.68+1.5%$37.45+111.8%+191.3%$969.50M$14.34M-4.51500 Related Companies and Tools Related Companies ARS Pharmaceuticals Competitors Dianthus Therapeutics Competitors Oric Pharmaceuticals Competitors Upstream Bio Competitors Spyre Therapeutics Competitors Pharming Group Competitors Urogen Pharma Competitors CorMedix Competitors atai Life Sciences Competitors uniQure Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFCR) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifecore Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LFCR Stock Alerts